SCHEMBL6450855

SCHEMBL6450855

O=C(O)CCc1ccc(NC(=O)c2cc(-c3ccc(OC(F)(F)F)cc3)cs2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 6/20 0.55
ABL1 P00519 1/20 0.54
MMP13 P45452 1/20 0.53
FFAR1 O14842 6/20 0.48
FFAR4 Q5NUL3 2/20 0.48
SCN10A Q9Y5Y9 1/20 0.44
NR1H4 Q96RI1 1/20 0.42
EPHX2 P34913 1/20 0.42
TRPV1 Q8NER1 1/20 0.42
ADCY6 O43306 1/20 0.42
ADCY3 O60266 1/20 0.42
ADCY9 O60503 1/20 0.42
ADCY5 O95622 1/20 0.42
ADCY8 P40145 1/20 0.42
GCGR P47871 1/20 0.42
ADCY7 P51828 1/20 0.42
ADCY2 Q08462 1/20 0.42
ADCY1 Q08828 1/20 0.42
ADCY4 Q8NFM4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6463245 0.90 MMP12 (0.56) MMP12ABL1MMP13SCN10ANR1H4
SCHEMBL6874175 0.88 MMP12 (0.57) MMP12MMP13FFAR1FFAR4NR1H4
SCHEMBL6880673 0.88 MMP12 (0.58) MMP12ABL1MMP13SCN10AEPHX2
SCHEMBL6457163 0.85 MMP12 (0.51) MMP12ABL1MMP13FFAR1FFAR4
SCHEMBL6152695 0.85 MMP12 (0.67) MMP12ABL1MMP13SCN10AEPHX2
SCHEMBL8342310 0.81 MMP12 (0.59) MMP12ABL1MMP13SCN10A
SCHEMBL6874004 0.81 MMP12 (0.55) MMP12ABL1MMP13FFAR1FFAR4
SCHEMBL6451590 0.81 ABL1 (0.57) MMP12ABL1MMP13SCN10A
SCHEMBL6141803 0.81 ABL1 (0.57) MMP12ABL1MMP13SCN10AEPHX2
SCHEMBL6450834 0.80 ABL1 (0.54) MMP12ABL1MMP13SCN10AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1534700-A1 NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME WARNER-LAMBERT COMPANY LLC (US) 2005-06-01 EP claimed
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them WARNER-LAMBERT COMPANY LLC 2004-04-15 US claimed
WO-2004018448-A1 NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME WARNER-LAMBERT COMPANY LLC (US) 2004-03-04 WO claimed
EP-1394159-A1 New thiophene derivatives, process for their preparation and pharmaceutical compositions containing them Warner-Lambert Company LLC (US) 2004-03-03 EP claimed
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them WARNER-LAMBERT COMPANY LLC 2004-04-15 US disclosed
WO-2004018448-A1 NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME WARNER-LAMBERT COMPANY LLC (US) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them MMP11, MMP13, CBR1 MMP12 7/4885ABL1 2800/4885MMP13 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.